Prosight Management’s Ligand Pharmaceuticals LGND Stock Holding History

Prosight Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18,435	Closed	-$836K	–	58
2020 Q1	$836K	Buy	+18,435	New	+$1.04M	0.39%	36
2019 Q1	–	Sell	-20,198	Closed	-$1.71M	–	42
2018 Q4	$1.71M	Buy	+20,198	New	+$2.15M	0.88%	28

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

Prosight Management's LGND Position: Q2 2020 in Review

Prosight Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2020, closing a stake of 18,435 shares — an estimated $836K sold.

Prosight Management first reported a position in LGND in Q4 2018 and held it in 2 quarters. The position peaked at $1.71M in Q4 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q2 2020.

Prosight Management reported no remaining Ligand Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Prosight Management sold 18,435 Ligand Pharmaceuticals shares in Q2 2020, an estimated $836K.
Prosight Management first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Prosight Management's Ligand Pharmaceuticals position peaked at $1.71M in Q4 2018.
262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2020.

Based on Prosight Management's 13F filing for Q2 2020, filed 14 Aug 2020.